Stock CGEM CULLINAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Real-time Estimate Cboe BZX
Other stock markets
 12:36:47 2024-05-09 EDT 		5-day change 1st Jan Change
27.92 USD +0.70% Intraday chart for Cullinan Therapeutics, Inc. +1.34% +174.29%
09:21am Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing MT
04-29 Cullinan Therapeutics Appoints Mary Kay Fenton as CFO MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
AQ
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
GL
Cullinan Oncology : Therapeutics Corporate Update
PU
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
GL
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
AQ
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
GL
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
GL
Cullinan Oncology to Participate in Upcoming Investor Conferences
GL
Cullinan Oncology to Participate in Upcoming Investor Conferences
AQ
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
AQ
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
GL
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
GL
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
AQ
Cullinan Oncology to Participate in Upcoming Investor Conferences
GL
Cullinan Oncology to Participate in Upcoming Investor Conferences
AQ
Cullinan Oncology to Participate in Upcoming Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. News Cullinan Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW